Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transition to PP3M in Schizophrenia
NCT02713282Phase 3Completed
- Sponsor
- Janssen-Cilag
- Start
- Apr 2016
- Primary completion
- Mar 2018
- Modality
- Metabolically Activated Prodrugs
- Countries
- 15
01
Overview
A Phase 3 trial of paliperidone palmitate in schizophrenia, sponsored by Janssen-Cilag. Started Apr 2016; status: completed.
02
Drugs
paliperidone palmitate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02713282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02713282.